Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 10/20 | 0.59 |
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | GAA | P10253 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | SNCA | P37840 | 3/20 | 0.59 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274184 | 0.82 | NOX1 (0.67) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL10530491 | 0.82 | NOX1 (0.67) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL31331504 | 0.78 | NOX1 (0.61) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL194062 | 0.78 | NOX1 (0.61) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL1868575 | 0.77 | NOX1 (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL88106 | 0.77 | NOX1 (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL560873 | 0.77 | NOX1 (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL290846 | 0.77 | NOX1 (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL4534080 | 0.77 | NOX1 (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL344333 | 0.77 | NOX1 (0.59) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | disclosed |
| CN-114901640-A | Novel compounds useful for the treatment of dyslipidemia | 兹杜斯生命科学有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220204453-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-06-30 | — | — | US | disclosed |
| EP-4019520-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-06-29 | — | — | EP | disclosed |
| CN-114671873-A | Heterocyclic compound, organic light-emitting device including heterocyclic compound, and electronic apparatus including organic light-emitting device | 三星电子株式会社 | 2022-06-28 | — | — | CN | disclosed |
| WO-2022130352-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021130723-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| EP-3083587-B1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2018-04-04 | — | — | EP | disclosed |
| EP-3083587-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | Cadila Healthcare Limited (IN) | 2016-10-26 | — | — | EP | disclosed |
| US-20160083380-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| EP-1930339-A2 | Imide compound | MITSUI CHEMICALS, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1390664-A4 | MATERIALS, METHODS, AND USES FOR PHOTOCHEMICAL GENERATION OF ACIDS AND/OR RADICAL SPECIES | UNIV ARIZONA (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070259151-A1 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-7259260-B2 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-08-21 | — | — | US | disclosed |
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| US-20050208425-A1 | Imide compound and optical recording media made by using the same | YAMAMOTO CHEMICALS, INC. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1445115-A1 | IMIDE COMPOUNDS AND OPTICAL RECORDING MEDIA MADE BY USING THE SAME | Mitsui Chemicals, Inc. (JP) | 2004-08-11 | — | — | EP | disclosed |
| EP-1390664-A1 | MATERIALS, METHODS, AND USES FOR PHOTOCHEMICAL GENERATION OF ACIDS AND/OR RADICAL SPECIES | The Arizona Board of Regents (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002079691-A1 | MATERIALS, METHODS, AND USES FOR PHOTOCHEMICAL GENERATION OF ACIDS AND/OR RADICAL SPECIES | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | PCSK9, CETP, LCAT | NOX1 2118/4885MAPT 229/4885GAA 247/4885 |
| US-20220204453-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | CYP1A1, CYP2E1, CYP1A2 | NOX1 66/4885MAPT 2428/4885GAA 1912/4885 |
| US-20050208425-A1 | Imide compound and optical recording media made by using the same | CRY1, MTNR1A, TRPA1 | NOX1 291/4885MAPT 2420/4885GAA 4696/4885 |
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | NOX1 54/4885MAPT 4554/4885GAA 1738/4885 |
| US-20160083380-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | OAT, CYP11B2, CYP11B1 | NOX1 242/4885MAPT 752/4885GAA 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.